ASCO Gastrointestinal Cancers Symposium

Novel Drug-Chemo Combo May Offer ‘New Standard of Care’ for Certain GI Cancers

January 21st 2023, 7:00pm

Article

Zolbetuximab plus mFOLFOX6 lengthened the time to progression for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.

HER2-Low Gastric Cancer May Be a Distinct Disease Subtype

January 20th 2023, 10:00pm

Article

Patients with HER2-low gastric cancer tended to have distinct characteristics compared to those with HER2-negative or -positive disease, warranting more research into this group, research found.

New Drug Combination May Improve Outcomes in Unresectable Liver Cancer

January 27th 2022, 10:00pm

Article

An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.

Adagrasib Confers High Response Rates in Several Gastrointestinal, Pancreatic Tumors

January 26th 2022, 10:00pm

Article

Single-agent adagrasib was associated with encouraging treatment responses in patients with previously treated non-colorectal gastrointestinal tumors and pancreatic ductal adenocarcinoma.

Oral Antimetabolite After Surgery Associated With Survival Benefit in Biliary Tract Cancer

January 26th 2022, 8:00pm

Article

Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.

Keytruda Plus Mektovi and Avastin Associated With Survival Benefit in Metastatic Colon Cancer

January 25th 2022, 4:17pm

Article

A group of patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer experienced responses to treatment with Keytruda plus Mektovi and Avastin.

Blood Test Results May Identify Which Patients With CRC May Benefit From Post-Surgical Chemotherapy

January 25th 2022, 2:11pm

Article

The use of a ctDNA assay could help determine which patients with colorectal cancer may benefit most from chemotherapy after surgery.

Gut Microbiome Makeup May Help Predict Skin-Related Immunotherapy Side Effects in Patients With Gastric Cancer

January 24th 2022, 4:00pm

Article

Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.

Patients With Unresectable Liver Cancer May Have a ‘Promising and Tolerable’ Treatment Option With Combination Therapy

January 24th 2022, 2:21pm

Article

The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.

Lenvima May Offer Survival Benefit With Manageable Side Effects in Recurrent HCC After Liver Transplantation

January 23rd 2022, 3:00pm

Article

Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.